Long-term outcomes of renal transplantation: A result of the original endowment of the donor kidney and the inflammatory response to both alloantigens and injury

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 6, 2000, Pages 643-648

  Vazquez, Miguel A ^a   Jeyarajah, D Rohan ^a   Kielar, Mariusz L ^a   Lu, Christopher Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIINFLAMMATORY AGENT;

ALLOIMMUNITY; BRAIN DEATH; CADAVER DONOR; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INFLAMMATION; KIDNEY DONOR; KIDNEY INJURY; KIDNEY MASS; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; NEPHRON; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INTRAOPERATIVE COMPLICATIONS; ISOANTIGENS; KIDNEY; KIDNEY TRANSPLANTATION; NEPHRITIS; TISSUE DONORS; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 0033677708     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200011000-00009     Document Type: Review

References (65)

1. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
2. Renal mass: An important determinant of late allograft outcome
3. The 'injury response': A concept linking nonspecific injury, acute rejection, and long-term transplant outcomes
4. Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process?
5. Brain death and its influence on donor organ quality and outcome after transplantation
6. Posttransplantation acute tubular necrosis: Risk factors and implications for graft survival
7. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys
8. Time dependency of factors affecting renal allograft survival
9. Delayed graft function: Risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation
10. Delayed graft function: Risk factors and implications for renal allograft survival
11. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection
12. Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction
13. Telomere shortening in kidneys with age
14. Early experience with dual kidney transplantation in adults using expanded donor criteria
15. Impact of pre-existing donor hypertension and diabetes mellitus on cadaveric renal transplant outcomes
16. Fibrous intimal thickening at implantation as a risk factor for the outcome of cadaveric renal allografts
17. Are wedge biopsies of cadaveric kidneys obtained at procurement reliable?
18. Glomerulosclerosis as a determinant of posttransplant function of older donor renal allografts
19. Donor γ protein beta 3 subunit 825TT genotype is associated with reduced kidney allograft survival
20. Adhesion molecule polymorphisms in chronic renal allograft failure
21. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
22. Improved graft survival after renal transplantation in the United States, 1988 to 1996
23. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection
24. Determinants of graft survival after renal transplantation
25. The Banff '97 working classification of renal allograft pathology
26. Long-term renal allograft survival: Prognostic implication of the timing of acute rejection episodes
27. Features of acute rejection that increase risk for chronic rejection
28. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
29. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study
30. The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies
31. Focal infiltrates in kidney allografts: Developing a model for clinical transplant peripheral tolerance
32. Immunologic and nonimmunologic factors: Different risks for cadaver and living donor transplantation
33. Effect of initial slow graft function on renal allograft rejection and survival
34. Impact of acute rejection and early allograft function on renal allograft survival
35. Tolerance, danger, and the extended family
36. Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney
37. Dendritic cells and the control of immunity
38. Dendritic cells as regulators of immune reactivity: Implications for transplantation
39. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients
40. Renal transplantation from non-heart beating donors: A promising alternative to enlarge the donor pool
41. Renal transplantation from non-heart-beating donors: Opportunities and challenges
42. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation
43. Management of the cadaveric donor of a renal transplant: More than optimizing renal perfusion?
44. Chronic rejection: Increasing evidence for the importance of allogen-independent factors
45. Chronic rejection of renal transplants: New clinical insights
46. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
47. The role of protein traffic in the progression of renal diseases
48. Late graft dysfunction after prolonged cold ischemia of the donor kidney
49. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney
50. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals
51. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats
52. The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair
53. Donor treatment with mycophenolate mofetil: Protection against ischemia-reperfusion injury in the rat
54. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats
55. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
56. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat
57. Renal allograft protection with losartan in Fisher to Lewis rats: Hemodynamics, macrophages, and cytokines
58. The use of angiotensin-converting enzyme inhibitors in renal transplant patients
59. High survival rates of kidney transplants from spousal and living unrelated donors
60. Acute rejection of rat renal allografts is accelerated by donor brain death
61. Acute renal failure
62. Cadaver versus living donor kidneys: Impact of donor factors on antigen induction before transplantation